

1 **Title**

2 Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among
3 healthcare personnel in Pakistan: a test-negative, case-control study.

4 **Authors:**

5 Unab I. Khan MBBS, MS.

6 Associate Professor, Department of Family Medicine

7 Aga Khan University

8 PO BOX 3500, Stadium Road campus

9 Karachi, Pakistan

10

11 Imran Hassan, MBBS.

12 Senior Instructor, Department of Family Medicine

13 Aga Khan University

14 PO Box 3500, Stadium Road campus

15 Karachi, Pakistan

16

17 Mahnoor Niaz, MBBS.

18 Research Associate, Dean's Clinical Research Fellowship Program

19 Aga Khan University

20 PO BOX 3500, Stadium Road campus

21 Karachi, Pakistan

22

23 Syed Iqbal Azam, MSc.

24 Assistant Professor, Department of Community Health Sciences

25 Aga Khan University

26 PO Box 3500, Stadium Road campus

27 Karachi 74800, Pakistan

28

29 Zahra Hasan, PhD.

30 Professor, Department of Pathology

31 Aga Khan University

32 PO Box 3500, Stadium Road campus

33 Karachi 74800, Pakistan

34

- 35 Syed Faisal Mahmood, MBBS.
- 36 Associate Professor, Section of Infectious Diseases
- 37 Department of Medicine
- 38 Aga Khan University
- 39 PO Box 3500, Stadium Road campus
- 40 Karachi 74800, Pakistan
- 41
- 42 Asad Ali MBBS, MPH
- 43 Professor, Department of Pediatrics and Child Health
- 44 Aga Khan University
- 45 PO Box 3500, Stadium Road campus
- 46 Karachi 74800, Pakistan
- 47
- 48 Corresponding Author:
- 49 Unab I. Khan MBBS, MS.
- 50 Associate Professor, Department of Family Medicine
- 51 Aga Khan University

52 PO Box 3500, Stadium Road campus

53 Karachi 74800, Pakistan

54 Tel: +92 3486 4842

55 Email: unab.khan@aku.edu

56 **Word Count:** 2979

57 **Abstract**

58 **Objective** During the COVID-19 pandemic, several vaccines that were efficacious in
59 randomized controlled trials (RCTs) were authorized for mass vaccination. In developing
60 countries, inactivated vaccines were widely administered. While inactivated vaccines
61 have been deemed effective in reducing disease severity, for healthcare personnel
62 (HCPs), effectiveness against COVID-19 infections is also essential to reduce the risk to
63 vulnerable patients and ensure a stable healthcare workforce. In addition, there are
64 limited studies examining inactivated vaccines' effectiveness against emerging SARS-
65 CoV-2 variants in real-world settings. We aimed to estimate the effectiveness of
66 inactivated vaccines (BBIBP-CorV and CoronaVac) against RT-PCR-confirmed COVID-
67 19 infections among HCPs in the setting of emerging SARS-CoV-2 variants in Pakistan.

68 **Design, setting and participants** A retrospective matched test-negative case-control
69 analysis of existing data of HCPs at a private healthcare system in Pakistan.

70 **Methods** HCPs tested between April 1 and September 30, 2021, were included. Each
71 case was matched to two to six controls by the date of the RT-PCR test (± 7 days) to

72 reduce bias. We compared demographics, reasons for testing, and vaccination status
73 between cases and controls using chi-square for categorical variables and t-test for
74 continuous-level data. The odds of getting a PCR-confirmed SARS-COV-2 infection
75 were calculated using conditional logistic regression, after adjusting for age, gender, and
76 work area. Vaccine effectiveness (VE) was calculated as percent VE using $(1-OR)*100$.

77 **Results** Inactivated vaccines were ineffective against COVID-19 infections ≥ 14 days
78 after receiving the first dose [VE: 20% (95% CI: -10, 41; $p=0.162$)]. The vaccines
79 showed modest effectiveness ≥ 14 days after the second dose against COVID-19
80 infections [VE: 33% (95% CI: 11, 50; $p=0.006$)], and symptomatic COVID-19 infections
81 [VE: 36% (95% CI: 10, 54; $p=0.009$)].

82 **Conclusions** Inactivated vaccines show modest effectiveness against COVID-19
83 infections in the setting of emerging VOCs. This builds a strong case for boosters and/or
84 additional vaccination.

85 **Key Words** COVID-19; epidemiology; immunology; infection control.

86 INTRODUCTION

87 The coronavirus disease 2019 (COVID-19) pandemic impacted global health, and as of
88 December 9, 2022, more than 657 million COVID-19 cases and six million deaths have
89 been reported to the WHO (1). Mass vaccination remains a cornerstone of public health
90 interventions to counter the COVID-19 pandemic. Several vaccines have proven
91 efficacious in phase III trials and received emergency approval for mass vaccination
92 campaigns (2-4). As healthcare personnel (HCPs) are at a higher risk of contracting the
93 disease and can become a source of infection to vulnerable patients (5, 6), both Centers
94 for Disease Control (CDC) and WHO (World Health Organization) have recommended
95 that national vaccine strategies prioritize vaccination of HCPs (7, 8).

96 In Pakistan, the Government-driven vaccination campaign commenced in February 2021.
97 Vaccines with more than 50% efficacy in clinical trials were approved for mass
98 vaccination by the health regulatory authorities, and HCPs were prioritized for
99 vaccination (9). In the first phase, conventional inactivated vaccines BBIBP-CorV and
100 CoronaVac were administered. Over the next few months, replication-deficient
101 adenovector vaccines, including single-dose Ad5-nCoV (CanSino Bio) and the two-dose
102 ChAdOx1 nCoV-19 (Oxford-AstraZeneca), became available and were administered to
103 HCPs and the public (10).

104 While CoronaVac and BIBP-CorV were efficacious in clinical trials (11, 12) most were
105 conducted before SARS-CoV-2 variants of concern (VOCs) appeared. It, therefore,
106 became crucial to assess the effectiveness of these vaccines in real-world settings during

107 the emergence of VOCs. This information can provide critical insights to help with policy
108 decisions, including the need to give boosters or additional vaccination. We report the
109 effectiveness of BBIBP-CorV and CoronaVac vaccines against RT-PCR-confirmed
110 COVID-19 infections among HCPs, four months into the vaccination drive at a large
111 private healthcare system in Pakistan, with an existing robust employee surveillance
112 system. Our study was conducted in the setting of the third and fourth waves of COVID-
113 19 in Pakistan during which the alpha, beta, gamma, and delta variants were prevalent
114 (13, 14).

115 **METHODS**

116 **Study Design**

117 We conducted a matched, test-negative case-control study to evaluate the effectiveness of
118 inactivated vaccines (BBIBP-CorV and CoronaVac) in reducing the odds of RT-PCR-
119 confirmed COVID-19 infections in HCPs. Due to the rapidly changing vaccine uptake
120 and prevalence of the disease in the community, we used the test-negative case-control
121 design as recommended by the WHO (15). Our study population included all HCPs
122 working at AKU who were tested for SARS-CoV-2 by RT-PCR at the AKU Hospital
123 Clinical Laboratories between April 1 and September 30, 2021.

124 De-identified data was transferred from the Employee Health database to STATA v.15.0
125 for analysis. This study was approved by the Ethical Review Committee (ERC#: 2021-
126 5629-18170), AKU.

127 **Study Population**

128 *Inclusion Criteria*

- 129 • HCPs working at AKU and who got an RT-PCR test for SARS-CoV-2 at AKU
130 Hospital Clinical Laboratories between April 1 and September 30, 2021, AND
- 131 • HCPs who were unvaccinated or vaccinated with one or two doses of BBIBP-
132 CorV or CoronaVac.

133 *Exclusion Criteria*

- 134 • HCPs with missing vaccination data.
- 135 • HCPs who received other vaccines (Ad5-nCoV, AZD1222 (ChAdOx1), mRNA-
136 1273, Janssen (Johnson & Johnson), Gam-COVID-Vac, BNT162b2).
- 137 • HCPs who were enrolled in COVID-19 vaccine trials.

138 **Study Setting**

139 The Aga Khan University (AKU), a not-for-profit organization, runs a large healthcare
140 system within Pakistan. Its main campus in Karachi is a 750-bed tertiary care hospital, a
141 medical college, and a nursing school. Additionally, four secondary-care hospitals in two
142 cities, 19 integrated medical centers, and 290 laboratory collection centers in 120 cities
143 across Pakistan are part of the AKU healthcare system. The University employs 13960
144 staff, of which 80% are involved in direct health care (16).

145 Since the beginning of the pandemic, multiple policies were put in place to facilitate
146 HCPs getting tested. Free assessments, testing, and treatment were offered through the
147 Office of Employee Health in the Department of Family Medicine. In addition, time
148 away from work due to quarantine and isolation was not counted from HCPs' annual
149 leaves. For each employee who tested positive, detailed contact tracing was performed.
150 With these employee-friendly policies, HCPs have utilized the Office of Employee
151 Health; to date, 30,000 tests have been conducted.

152 HCPs were tested if: 1) they had symptoms consistent with COVID-19; 2) had a high-risk
153 exposure, as defined by the CDC criteria (17), to a person infected with COVID-19 either
154 in the community or at the workplace; or 3) were part of an outbreak investigation in a
155 specific part of the University. All testing was performed by SARS-CoV-2 polymerase
156 chain reaction on a nasal specimen using the Cobas® 6800 Roche assay (18). The
157 samples were collected at the HCPs' workplace, and all testing was done at the AKU
158 Hospital Clinical Laboratories, accredited by the College of American Pathologists, USA
159 (16).

160 Office of Employee Health maintained a password-protected database for COVID-19-
161 related data that is separate from HCPs' medical records. Once vaccination began, HCPs
162 also provided dates of vaccine administration and the type of vaccine. Vaccine
163 information was confirmed by verifying with the national database using the SMS-based
164 system developed by the Government of Pakistan (10). Vaccinations were available

165 without any priority policy to all AKU HCPs, regardless of age, comorbidities, area of
166 work, previous SARS-CoV-2 infections, etc.

167 **Definitions**

168 *Healthcare Personnel:* All employees working within the healthcare system with the
169 potential of direct and indirect exposure to patients or infectious material were considered
170 HCPs (19).

171 *Case:* HCPs who had a positive SARS-CoV-2 RT-PCR test during the study period and
172 had an absence of a positive test result in the preceding 90-day period.

173 *Control:* HCPs with a negative SARS-CoV-2 RT-PCR test result during the study period
174 and the absence of a positive test result in the preceding 90-day and the subsequent 14-
175 day period.

176 *Vaccination Status:* Using the WHO definition (20), we defined vaccination status at the
177 time of testing as:

- 178 • Unvaccinated: If no dose of any vaccine was received.
- 179 • Single dose received: If only the first dose of BBIBP-CorV or CoronaVac vaccine
180 was received. This group was further divided into two subgroups: a) 0–13 days
181 since receiving the first dose; b) ≥ 14 days since receiving the first dose of a two-
182 dose vaccine.

- 183 • Two doses received: If both doses of BBIBP-CorV or CoronaVac vaccine were
184 received. This group was also further divided into two: a) 0–13 days since
185 receiving the final dose; b) ≥ 14 days since receiving the final dose.

186 *COVID-19 Infection:* All HCPs who tested positive for SARS-CoV-2 by RT-PCR,
187 regardless of the presence or absence of symptoms.

188 *Symptomatic COVID-19:* All HCPs who tested positive for SARS-CoV-2 by RT-PCR
189 and had one or more COVID-19-related symptoms in 0-10 days before the RT-PCR test
190 for SARS-CoV-2.

191 *Work Area:* HCPs not working in direct clinical care (e.g. laboratory personnel,
192 housekeeping staff, food providers, and administrative staff) were classified as “non-
193 clinical”; those providing direct clinical care in areas not designated for patients with
194 COVID were classified as “clinical non-COVID”; whereas HCPs working in designated
195 areas for COVID-suspect or COVID-confirmed patients were categorized as “clinical
196 COVID.”

197 **Statistical analysis**

198 Data on demographics, results of the SARS-CoV2 RT-PCR test, vaccination status and
199 dates, reason for testing, work area, and previous RT-PCR tests (within the preceding 90-
200 day period) were retrieved from the Office of Employee Health’s database for statistical
201 analysis. Vaccination status was allocated based on pre-defined definitions stated above.

202 As the study was during the surge, with percent positivity changing weekly, we matched
203 cases and controls by the date of the RT-PCR test (± 7 days) to reduce bias. Each case
204 was matched to a minimum of two and a maximum of six controls.

205 We compared demographics, reason for testing, work area and vaccination status
206 between cases and controls using chi-square for categorical variables and t-test for
207 normally distributed continuous-level data. Using unvaccinated individuals as a
208 reference, we used conditional logistic regression to estimate the odds of having RT-
209 PCR-confirmed COVID-19 infections in HCPs vaccinated with a single dose and both
210 doses of the two-dose inactivated vaccines. We calculated unadjusted and adjusted odds
211 ratios, accounting for covariates that included age, sex (using females as a reference), and
212 work area (using non-clinical as a reference). Vaccine effectiveness was calculated as
213 Percent VE using $(1 - OR) * 100$. Additionally, we performed a subgroup analysis to assess
214 the effectiveness of vaccines against symptomatic COVID-19 infection.

215 Based on Hitchings et al study (21), we plotted the weekly positivity rate and cumulative
216 vaccine coverage from the time vaccines were introduced (January 2021) to the end of
217 the study period (end of delta surge in September 2021) to understand the impact of
218 vaccines on COVID-19 infections in the healthcare system.

219 **Patient and public involvement**

220 Patient and the public were not involved in the conduct of this study.

221 **RESULTS**

222 Between April 1 and September 30, 2021, 4599 HCPs were tested for SARS-COV-2 via
223 RT-PCR. Figure 1 shows the process for the selection of HCPs in analysis. After
224 exclusion, 4074 HCPs remained, of whom 1037 tested positive and were classified as
225 cases, and 3037 tested negative and were classified as controls. Of these, 3095 (959 cases
226 and 2136 controls) were tested for symptoms. Cases were matched to controls by the date
227 of the RT-PCR test (± 7 days). Each case was matched to two to six controls. No HCPs
228 had to be excluded due to non-matching.

229 Table 1 shows the characteristics of all cases and controls. Compared to controls, cases
230 were older (35.3 ± 9.7 vs. 33.1 ± 8.6 ; p-value < 0.001). 73.9% of cases and 74.8% of
231 controls were administered the BBIBP-CorV vaccine. 61.4% of cases and 60.3% of
232 controls had received the second dose at least 14 days before the test. Among HCPs that
233 had received both doses of vaccine before the RT-PCR test, there was no significant
234 difference in mean duration between the second dose and test between cases and controls
235 (94.8 ± 41.6 vs. 91.7 ± 45.1 days; p value=0.123).

236 **Table 1**

237 **Characteristics of all cases and controls (N=4074)**

Characteristics	Cases 1037 (25%)	Controls 3037 (75%)	P-value
Age, years (mean \pm SD)	35.3 ± 9.7	33.1 ± 8.6	<0.001
Age groups, n (%)			
19-29 years	363 (35.0)	1308 (43.1)	
30-39 years	378 (36.5)	1132 (37.3)	
40-49 years	184 (17.7)	411 (13.5)	

50-59 years	96 (9.3)	162 (5.3)	
60 and over	16 (1.5)	24 (0.8)	
Sex, n (%)			
Female	512 (49.4)	1616 (53.2)	0.03
Male	525 (50.6)	1421 (46.8)	
Work area, n (%)			
Non-clinical	307 (29.6)	956 (31.5)	0.001
Clinical non-COVID	673 (64.9)	1813 (59.7)	
Clinical COVID	57 (5.5)	268 (8.8)	
Reason for testing, n (%)			
Outbreak	6 (0.6)	130 (4.3)	
Exposure	72 (6.9)	771 (25.4)	<0.001
Symptoms	959 (92.5)	2136 (70.4)	
Vaccination status, n (%)			
Unvaccinated	102 (9.8)	314 (10.3)	
Single dose, 0-13 days	18 (1.7)	58 (1.9)	
Single dose, ≥ 14 days	264 (25.5)	762 (25.1)	0.532
Two doses, 0-13 days	16 (1.5)	73 (2.4)	
Two doses, ≥ 14 days	637 (61.4)	1830 (60.3)	
Vaccine name, n (%)			
Unvaccinated	102 (9.8)	314 (10.3)	
BBIBP-CorV	766 (73.9)	2271 (74.8)	0.534
CoronaVac	168 (16.2)	450 (14.8)	
Interval between first dose and RT-PCR test in HCPs with only a single dose of vaccine, days (mean \pm SD)	113.5 \pm 49.5	114.8 \pm 53.9	0.498
Interval between second dose and RT-PCR test in HCPs with two doses of vaccine, days (mean \pm SD)	94.8 \pm 41.6	91.7 \pm 45.1	0.123

238 SD: standard deviation; RT-PCR: reverse transcription polymerase chain reaction; HCP: health

239 care personnel; IQR: interquartile range

240 Table S1 describes the characteristics of symptomatic cases and controls (3095/4074

241 (76.0%). There was no significant difference in the mean interval between the onset of

242 symptoms and the RT-PCR test between cases and controls (2.1 ± 2.0 vs. 1.9 ± 2.3 days;

243 $p=0.017$).

244 Table 2 shows the odds of contracting COVID-19 infection by the time since vaccination.
 245 After adjusting for age, sex, and work area, we found that a single dose of the two-dose
 246 vaccines was ineffective within the first 13 days [VE: 30% (95% CI: -26, 62; p=0.234)]
 247 or even after 13 days had elapsed [VE: 20% (95% CI: -10, 41; p=0.162)]. This shows that
 248 one dose is not enough to prevent COVID-19 infections. While the vaccines were
 249 effective during the period < 14 days after the second dose [VE: 44% (95% CI: -2, 69;
 250 p=0.055)], the results were not significant. The vaccines were most effective ≥ 14 days
 251 after the second dose against a COVID-19 infection [VE: 33% (95% CI: 11, 50;
 252 p=0.006)].

253 **Table 2**

254 **Effectiveness of inactivated vaccines against all COVID-19 infections (symptomatic**
 255 **and asymptomatic) (matched case-control)**

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	Vaccine effectiveness**, % (95% CI)	P value
Model		0.098			<0.001
Unvaccinated	1		1		
Single dose, < 14 days	0.76 (0.42, 1.37)	0.354	0.70 (0.38, 1.26)	30 (-26, 62)	0.234
Single dose, ≥ 14 days	0.83 (0.6, 1.12)	0.223	0.80 (0.59, 1.1)	20 (-10, 41)	0.162
Two doses, < 14 days	0.58 (0.32, 1.04)	0.069	0.56 (0.31, 1.02)	44 (-2, 69)	0.055
Two doses, ≥ 14 days	0.72 (0.54, 0.96)	0.024	0.66 (0.50, 0.89)	33 (11, 50)	0.006

256 *: adjusted for age, sex, work area.

257 **: Vaccine Effectiveness= (1-aOR)*100

258 Table 3 shows the odds of contracting symptomatic COVID-19 infection by the time
 259 since vaccination. After adjusting for age, sex, and work area, we found that the first dose
 260 was ineffective against a symptomatic COVID-19 infection. The vaccines were most
 261 effective ≥ 14 days after the second dose against a symptomatic COVID-19 infection
 262 [VE: 36% (95% CI: 10, 54; p=0.009)].

263 **Table 3**

264 **Effectiveness of inactivated vaccines against symptomatic COVID-19 infections**
 265 **(matched case-control)**

	Unadjusted analysis		Adjusted analysis*		
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	Vaccine effectiveness**, % (95% CI)	P value
Model		0.208			<0.001
Unvaccinated	1		1		
Single dose, < 14 days	0.82 (0.42, 1.57)	0.546	0.71 (0.36, 1.38)	29 (-38, 64)	0.295
Single dose, ≥ 14 days	0.76 (0.53, 1.08)	0.125	0.75 (0.52, 1.07)	25 (-7, 48)	0.101
Two doses, < 14 days	0.60 (0.31, 1.15)	0.122	0.60 (0.31, 1.16)	40 (-16, 69)	0.131
Two doses, ≥ 14 days	0.69 (0.5, 0.96)	0.027	0.64 (0.46, 0.90)	36 (10, 54)	0.009

266 *: adjusted for age, sex, work area.

267 **: Vaccine Effectiveness= (1-aOR)*100

268 Figure 2 displays the weekly RT-PCR tests conducted and the cumulative coverage of the
 269 first and second dose of inactivated vaccines among HCPs at our institution. We see that

270 despite 75% coverage with 2-doses of inactivated vaccines, we observed an increase in
271 positivity rates that correlated with the delta surge in Pakistan. This also shows the
272 modest effectiveness of inactivated vaccines against VOCs.

273 **DISCUSSION**

274 Our study among HCPs found that BBIBP-CorV and CoronaVac were not as effective as
275 seen in the efficacy trials (11, 12) in preventing COVID-19 infections, even 14 days after
276 the second dose of the two-dose vaccines. Vaccines did not provide significant protection
277 against infection after the first dose and within the first two weeks of the second dose.
278 During our study period, the predominant variants in Pakistan switched from alpha, beta
279 and gamma in April to June (13, 14) to the highly transmissible delta constituting up to
280 99% of the total genomes sequenced from July to September 2021 (22).

281 Existing evidence on the effectiveness of inactivated vaccines against infections is
282 inconsistent. Our results agree with a test-negative case-control study conducted in Brazil
283 among healthcare workers during the gamma variant epidemic, which reported modest
284 effectiveness of two doses of CoronaVac, with adjusted effectiveness of 37.1% against
285 symptomatic COVID-19 infections and 37.9% against all COVID-19 infections (21).

286 Similarly, moderate effectiveness against COVID-19 infections was estimated for
287 inactivated vaccines during the delta variant epidemic in China (23, 24). In contrast, the
288 effectiveness estimated in our study is lower than that of CoronaVac reported among
289 healthcare workers in Turkey (65%) (25).

290 Several possibilities exist for the lower-than-expected effectiveness of inactivated
291 vaccines in our study. Neutralizing antibody levels correlate with protection against
292 COVID-19 infections (26, 27), and inactivated vaccines produce inferior antibody
293 responses compared to mRNA vaccines (9, 28-30). Moreover, the weakened
294 neutralization potency of inactivated vaccines against the dominant VOCs circulating
295 during our study period, especially the vaccine-resistant delta variant, may have
296 contributed to the limited effectiveness (30, 31). Indeed, studies conducted during the
297 delta variant epidemic have demonstrated only modest effectiveness of two doses of
298 BBIBP-CorV and CoronaVac against infections (23, 32).

299 The mean interval between the second dose of vaccine and COVID-19 infection was
300 more than 90 days in our study. Studies have demonstrated a decline in neutralizing
301 antibody titers three months after vaccinations with the two-dose BBIBP-CorV and
302 CoronaVac (30, 33, 34). It is possible that there was a significant waning of neutralizing
303 antibody responses in our study population. Considering that inactivated vaccines were
304 the most widely used vaccines in low-middle-income countries (LMICs), this finding
305 supports the provision of homologous or heterologous booster doses among recipients of
306 these vaccines.

307 Our study has limitations. Our sample size did not allow us to match more than one
308 variable. However, we did adjust for age, sex, and work area in the logistic model.
309 Additionally, most HCPs in our setting did not get the severe disease or require
310 hospitalization during the study period. Therefore, we cannot comment on vaccines'

311 effectiveness against severe disease. It is, however, essential to note that in healthcare
312 settings, infected HCPs can risk spreading the infection to vulnerable patients. Thus, it is
313 vital to examine not only from the perspective of the infected person but its impact on the
314 system at large. As samples from HCPs in our study population did not undergo genomic
315 sequencing, we could not directly ascertain effectiveness against the circulating VOCs.
316 Finally, our study was conducted on HCPs and the results may not be generalizable to the
317 population outside of healthcare settings.

318 Despite these limitations, our study has clear strengths. Our findings are from a large,
319 well-defined group of HCPs with consistent testing parameters that did not change during
320 the study period. We used RT-PCR which is sensitive to detecting SARS-CoV-2
321 infections (18). Moreover, the vaccine status was highly accurate as it was validated
322 through the national vaccine registry. Using a test-negative design, we mitigated the risk
323 of bias/confounding associated with healthcare access and seeking behavior. Finally, our
324 study was conducted among HCPs whose well-being is imperative to continue to offer
325 uninterrupted, quality care to patients in a pandemic.

326 Our study was conducted in an LMIC with a high population density and limited
327 resources. Thus, examining the effectiveness of vaccines in these settings is essential to
328 prevent public health crises. Pakistan and other developing economies with weak
329 healthcare systems need effective vaccines to meet the unprecedented challenge of
330 dealing with the morbidity and mortality associated with COVID-19. Our study adds new
331 estimates to the effectiveness of these vaccines in HCPs. It may guide future policies in

332 Pakistan and other LMICs that mainly administered inactivated vaccines in their mass
333 vaccination campaigns. By finding complete vaccination with CoronaVac and BBIBP-
334 CorV vaccines to be only modestly effective against COVID-19 infections, our study
335 strengthens the case for boosters or additional vaccination among recipients of these
336 vaccines. Additionally, with new variants being identified regularly, it is crucial to
337 prioritize conducting studies at different times and in various settings to continuously
338 examine the effectiveness of these vaccines and boosters against the prevailing variants in
339 real-world settings.

340 **CONCLUSIONS**

341 Absence of strong effectiveness of inactivated vaccines against COVID-19 infections
342 among HCPs, especially during the spread of VOCs in our setting is concerning and
343 builds a case for boosters and/or additional vaccination. There is a need for further
344 studies to continuously assess effectiveness in the setting of emerging variants to guide
345 policies regarding boosters to ensure adequate protectiveness.

346 **Author Contributions:**

347 Conception and design: UIK, IH, AA

348 Analysis and Interpretation: UIK, IH, IA, MN

349 Drafting and Revising manuscript: MN, ZH, SFM, AA, IH, UIK

350 Final approval of manuscript: UIK

351 **Acknowledgments**

352 We acknowledge the support of Professor Adil Haider, Dean AKU-Medical College and
353 Professor Shahid Shafi, previous CEO of Aga Khan University Hospital, Pakistan. In
354 addition, we thank the Employee Health team Shehreen Somani RN, Sania Nawaz RN,
355 Noorjehan Momin RN, Dr. Asif Hakim, and the entire Family Medicine team for
356 providing care to employees.

357 **Ethics Statements**

358 **Participants consent to participate** Deidentified data was used for analysis and consent
359 was not required.

360 **Ethics Approval** This study was approved by the Ethical Review Committee (ERC#:
361 2021-5629-18170), Aga Khan University.

362 **Competing interests**

363 All authors declare no conflicts of interest, support or financial relationship with any
364 organization or other activities with any influence on the submitted work.

365 **Data availability**

366 As this is employee-related data, we do not have permission to make it publicly
367 accessible. However, data are available from the corresponding author after approval
368 from the University's ethics review committee on reasonable request.

369 **Funding**

370 This research received no specific grant from any funding agency in the public,
371 commercial or not-for-profit sectors.

372

373 References

- 374 1. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; cited January 9,
375 2023 [Available from: <https://covid19.who.int/>.
376 2. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
377 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
378 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*.
379 2021;397(10269):99-111.
380 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
381 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-15.
382 4. Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and Safety of COVID-19
383 Vaccines in Phase III Trials: A Meta-Analysis. *Vaccines (Basel)*. 2021;9(6).
384 5. Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment
385 and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-
386 COVID-19 hospitals in Southern Switzerland. *The Lancet Regional Health - Europe*.
387 2021;1:100013.
388 6. Vitrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, et al. Effect of
389 Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection
390 among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. *Vaccines*
391 (Basel). 2021;9(8).
392 7. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The
393 Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial
394 Supplies of COVID-19 Vaccine - United States, 2020. *MMWR Morb Mortal Wkly Rep*.
395 2020;69(49):1857-9.
396 8. World Health O. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in
397 the context of limited supply: an approach to inform planning and subsequent recommendations
398 based on epidemiological setting and vaccine supply scenarios, first issued 20 October 2020,
399 latest update 16 July 2021. Geneva: World Health Organization; 2021 2021. Contract No.:
400 WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2021.1.
401 9. Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al.
402 Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers.
403 *Vaccines (Basel)*. 2021;9(11).
404 10. COVID-19 Health Advisory Platform by Ministry of National Health Services
405 Regulations & Coordinations GoP.
406 11. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2
407 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A
408 Randomized Clinical Trial. *Jama*. 2021;326(1):35-45.
409 12. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and
410 safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a
411 double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet*.
412 2021;398(10296):213-22.
413 13. Nasir A, Aamir UB, Kanji A, Samreen A, Ansar Z, Ghanchi NK, et al. SARS-CoV-2
414 Variants of Concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron coincident with
415 consecutive pandemic waves in Pakistan. *medRxiv*. 2022:2022.05.19.22275149.

- 416 14. Hasan Z, Aamir U, Nasir A, Kanji A, Samreen A, Bukhari A, et al. Changing SARS-
417 CoV-2 variants in Karachi, Pakistan from alpha to delta through COVID-19 waves three and
418 four2021.
- 419 15. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of
420 limited supply: an approach to inform planning and subsequent recommendations based on
421 epidemiological setting and vaccine supply scenarios. *who.int/publications*: World Health
422 Organization; 2021 [updated 21 January 2022; cited 2022 13 January 2022]. Available from:
423 [https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-](https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines)
424 [vaccines](https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines).
- 425 16. AKUH Clinical Laboratory Re-Accredited by the College of American Pathologists for
426 the Third Time 2022 [Available from:
427 [https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/re-accreditation-of-akuh-laboratories-](https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/re-accreditation-of-akuh-laboratories-for-the-third-time.aspx)
428 [for-the-third-time.aspx](https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/re-accreditation-of-akuh-laboratories-for-the-third-time.aspx)].
- 429 17. Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or
430 Exposure to SARS-CoV-2: Centers for Disease Control and Prevention; 2020 [updated 21 January
431 2022 13 January 2022]. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assessment-hcp.html)
432 [ncov/hcp/guidance-risk-assessment-hcp.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assessment-hcp.html).
- 433 18. Roche receives FDA authorisation for testing of asymptomatic people with the cobas
434 SARS-CoV-2 Test to help control the spread of COVID-19 [press release]. 2021.
- 435 19. Kuhar DT, Carrico R, Cox K, de Perio MA. Infection Control in Healthcare Personnel.
436 Appendix 2: Terminology: U.S. Department of Health and Human Services; 2019 [updated
437 October 2, 2019].
- 438 20. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation
439 of post-introduction COVID-19 Vaccine Effectiveness: Summary of interim guidance of the
440 World Health Organization. *Vaccine*. 2021.
- 441 21. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.
442 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
443 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *Lancet Reg*
444 *Health Am*. 2021;1:100025.
- 445 22. Umair M, Ikram A, Rehman Z, Haider SA, Ammar M, Badar N, et al. Genomic diversity
446 of SARS-CoV-2 in Pakistan during the fourth wave of pandemic. *J Med Virol*.
447 2022;94(10):4869-77.
- 448 23. Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, et al. Effectiveness of Inactivated
449 COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta
450 Variant: Real World Study and Evidence - China, 2021. *China CDC Wkly*. 2022;4(4):57-65.
- 451 24. Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. Effectiveness of Inactivated COVID-19
452 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in
453 Guangdong, China : A Cohort Study. *Ann Intern Med*. 2022;175(4):533-40.
- 454 25. Copur B, Surme S, Sayili U, Tuncer G, Pehlivanoglu F, Sengoz G. Effectiveness of
455 CoronaVac vaccination against COVID-19 development in healthcare workers: real-life data.
456 *Future Microbiology*. 2022;17(17):1381-91.
- 457 26. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
458 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
459 SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-11.

- 460 27. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
461 Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*.
462 2021;39(32):4423-8.
- 463 28. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the
464 immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology*.
465 2022;27(4):301-10.
- 466 29. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of
467 mRNA and inactivated vaccines against COVID-19. *Lancet Microbe*. 2021;2(9):e423.
- 468 30. Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against
469 SARS-CoV-2 variants of concern among vaccinees in Hong Kong. *EBioMedicine*.
470 2022;77:103904.
- 471 31. Yu X, Wei D, Xu W, Liu C, Guo W, Li X, et al. Neutralizing activity of BBIBP-CorV
472 vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. *Nat*
473 *Commun*. 2022;13(1):1788.
- 474 32. Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwatarat N,
475 Satdhabudha A, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens
476 during the delta variant-dominant pandemic: a test-negative case-control study. *Emerg Microbes*
477 *Infect*. 2022;11(1):585-92.
- 478 33. Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe
479 A, et al. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. *Immun*
480 *Inflamm Dis*. 2022;10(6):e621.
- 481 34. Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, et al. Waning COVID-
482 19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
483 *Int J Infect Dis*. 2022;119:69-76.

484

485

486

487 **Figure Legends:**

488

489 **Figure 1**

490 Process for the selection of HCPs.

491 *Other vaccines: Ad5-nCoV (n=342), AZD1222 (ChAdOx1) (n=60), mRNA-1273 (n=20),

492 Janssen (n=1), Gam-COVID-Vac (n=18), BNT162b2 (n=11).

493

494 **Figure 2**

495 Weekly number of RT-PCR tests conducted and cumulative coverage of inactivated vaccines

496 (BBIBP-CorV and CoronaVac) among HCPs at our institution from January 1-September 30,

497 2021. Negative and positive RT-PCR tests are represented as red and blue bars, respectively.

498 Cumulative coverage of first and second dose of inactivated vaccines is shown by the yellow and

499 green lines, respectively. Our study period, April 1-September 30, 2021, is highlighted in pink.

April 1 -September 30, 2021
4599 HCPs got RT-PCR for SARS-CoV-2

468 excluded

- 452 had received other* vaccines
- 8 were enrolled in COVID-19 trials
- 8 were missing vaccination data

4131 HCPs

1042 RT-PCR positive

3089 RT-PCR negative

5 excluded with positive RT-PCR in preceding 90 days

52 excluded
37 with positive RT-PCR in preceding 90 days
15 with positive RT-PCR in subsequent 14 days

1037 cases
(959 tested for symptoms)

3037 controls
(2136 tested for symptoms)

Matching cases and controls (1:2 up to 6)

